INDOCO REMEDIES
Quarterly Results Analysis [Dec2023]
INDOCO REMEDIES Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 Audited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 Audited |
Jun2022 Audited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹459 Cr | ₹482 Cr | ₹427 Cr | ₹428 Cr | ₹399 Cr | ₹433 Cr | ₹408 Cr | ₹409 Cr |
Expenses | ₹397 Cr | ₹410 Cr | ₹365 Cr | ₹363 Cr | ₹337 Cr | ₹345 Cr | ₹337 Cr | ₹329 Cr |
Operating Income | ₹63 Cr | ₹71 Cr | ₹61 Cr | ₹65 Cr | ₹62 Cr | ₹88 Cr | ₹71 Cr | ₹81 Cr |
Other Income | ₹2 Cr | ₹4 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
Interest | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹9 Cr | ₹7 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr |
Depreciation | ₹24 Cr | ₹21 Cr | ₹20 Cr | ₹18 Cr | ₹17 Cr | ₹16 Cr | ₹20 Cr | ₹18 Cr |
Profit Before Tax | ₹23 Cr | ₹46 Cr | ₹34 Cr | ₹39 Cr | ₹38 Cr | ₹67 Cr | ₹48 Cr | ₹60 Cr |
Profit After Tax | ₹16 Cr | ₹35 Cr | ₹24 Cr | ₹26 Cr | ₹28 Cr | ₹50 Cr | ₹39 Cr | ₹40 Cr |
EPS | ₹1.77 | ₹3.81 | ₹2.65 | ₹2.80 | ₹3.05 | ₹5.40 | ₹4.19 | ₹4.39 |
Industry Peers & Returns | 1W | 1M | 1Y |
INDOCO REMEDIES | 2.7% | -0.6% | 2.7% |
SUN PHARMACEUTICAL INDUSTRIES | 0.3% | -7.5% | 53.9% |
CIPLA | 1.1% | -4.8% | 56.4% |
DR REDDYS LABORATORIES | 1.6% | 1.6% | 27.6% |
ZYDUS LIFESCIENCES | 5.2% | -0.2% | 90.1% |
DIVIS LABORATORIES | -1.9% | 10.7% | 21.4% |
MANKIND PHARMA | -2.3% | 0.1% | NA |
TORRENT PHARMACEUTICALS | 1.6% | 2% | 61.8% |
LUPIN | 2.4% | 2% | 132.5% |
INDOCO REMEDIES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -4.63 % |
Y-o-Y | 15.09 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹459 Cr | -4.63 | |
Sep2023 | ₹482 Cr | 12.95 | |
Jun2023 | ₹427 Cr | -0.39 | |
Mar2023 | ₹428 Cr | 7.25 | |
Dec2022 | ₹399 Cr | -7.81 | |
Sep2022 | ₹433 Cr | 6.08 | |
Jun2022 | ₹408 Cr | -0.22 | |
Mar2022 | ₹409 Cr | - |
INDOCO REMEDIES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -11.87 % |
Y-o-Y | 1.39 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹63 Cr | -11.87 | |
Sep2023 | ₹71 Cr | 16.67 | |
Jun2023 | ₹61 Cr | -5.54 | |
Mar2023 | ₹65 Cr | 4.38 | |
Dec2022 | ₹62 Cr | -29.38 | |
Sep2022 | ₹88 Cr | 22.95 | |
Jun2022 | ₹71 Cr | -11.29 | |
Mar2022 | ₹81 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -7.62 % |
Y-o-Y | -11.90 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 13.69% | -7.62 | |
Sep2023 | 14.82% | 3.35 | |
Jun2023 | 14.34% | -5.22 | |
Mar2023 | 15.13% | -2.64 | |
Dec2022 | 15.54% | -23.41 | |
Sep2022 | 20.29% | 15.94 | |
Jun2022 | 17.5% | -11.12 | |
Mar2022 | 19.69% | - |
INDOCO REMEDIES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -55.85 % |
Y-o-Y | -44.72 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹16 Cr | -55.85 | |
Sep2023 | ₹35 Cr | 45.74 | |
Jun2023 | ₹24 Cr | -6.32 | |
Mar2023 | ₹26 Cr | -8.31 | |
Dec2022 | ₹28 Cr | -43.39 | |
Sep2022 | ₹50 Cr | 28.93 | |
Jun2022 | ₹39 Cr | -4.65 | |
Mar2022 | ₹40 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -53.69 % |
Y-o-Y | -51.91 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 3.39 % | -53.69 | |
Sep2023 | 7.32 % | 29.10 | |
Jun2023 | 5.67 % | -5.97 | |
Mar2023 | 6.03 % | -14.47 | |
Dec2022 | 7.05 % | -38.59 | |
Sep2022 | 11.48 % | 21.48 | |
Jun2022 | 9.45 % | -4.45 | |
Mar2022 | 9.89 % | - |
INDOCO REMEDIES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -53.54 % |
Y-o-Y | -41.97 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹1.77 | -53.54 | |
Sep2023 | ₹3.81 | 43.77 | |
Jun2023 | ₹2.65 | -5.36 | |
Mar2023 | ₹2.8 | -8.20 | |
Dec2022 | ₹3.05 | -43.52 | |
Sep2022 | ₹5.4 | 28.88 | |
Jun2022 | ₹4.19 | -4.56 | |
Mar2022 | ₹4.39 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD